Everyday Health11h
RSV Vaccine: What You Need to Know
Learn about this vaccine that protects against a common seasonal virus that can sometimes cause severe disease, with info on ...
GlobalData on MSN1d
GSK gains approval in Japan for extended indication of RSV vaccine
GlaxoSmithKline (GSK) has received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for its regulatory ...
Optimistic Buy Rating for GlaxoSmithKline: Undervalued Stock with Promising Growth Prospects
GlaxoSmithKline (GSK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Justin Smith from ...
GSK's RSV vaccine gets Japan approval for adults aged 50 to 59
GSK said on Friday that its respiratory syncytial virus (RSV) vaccine has received approval in Japan for expanded use in ...
FiercePharma27d
GSK tries to steady the ship as Arexvy sales plummet in wake of CDC guidance changes
For the company’s closely watched respiratory syncytial virus (RSV) vaccine Arexvy, those challenges led to drastically reduced sales. After a stunning ascension to blockbuster status in its RSV ...
GSK announces Japan’s MHLW approved application to extend indication of Arexvy
GSK (GSK) announced that Japan’s Ministry of Health, Labour and Welfare, MHLW, has approved a regulatory application to extend the indication of Arexvy for the prevention of RSV disease to include ...
Pharmabiz3d
Japan’s MHLW grants expanded indication approval to GSK’s RSV vaccine, Arexvy for adults aged 50-59 at increased risk of severe RSV disease
GSK plc announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved a regulatory application to extend the indication of Arexvy (respiratory syncytial virus vaccine, recombinant ...
devdiscourse4d
Global Health Crises and Innovations: From Tainted Alcohol Tragedies to New Medical Advances
The latest health news includes the tragic death of two Australians from methanol poisoning in Laos, approval of GSK's RSV ...
Business Insider5d
GSK Plc Announces Regulatory Expansion For Arexvy In Japan To Include Adults Aged 50-59
(RTTNews) - GSK plc (GSK, GSK.L) announced that Japan's Ministry of Health, Labour and Welfare has approved a regulatory application to extend the indication of Arexvy for the prevention of RSV ...
Yahoo Finance1mon
Clover Announces Positive Clinical Data for RSV Vaccine Candidate SCB-1019 Compared Head-to-Head Versus GSK's AREXVY
RSV-A nAbs: SCB-1019 induced GMTs in RSV-A nAbs of approximately 30,500 IU/mL, compared to approximately 26,700 IU/mL for AREXVY and approximately 3,300 IU/mL for placebo at Day 28. RSV-B nAbs ...
The Financial Times28d
GSK lowers vaccine sales forecast as weak demand for RSV jab Arexvy takes toll
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. GSK has lowered its vaccine sales forecast for the year because of weak demand for its new respiratory ...
London South East5d
GSK's Arexvy approved for wider age range in Japan
(Sharecast News) - Biopharma giant GSK has announced that Japanese regulators have expanded the approved use of its Arexvy vaccine for severe respiratory syncytial virus (RSV) disease to a wider ...